DYRK1A and neurodegenerative disease: We seek to develop a potent and selective negative allosteric modulator of “Dual-specificity tyrosine-(Y)-phosphorylation Regulated Kinase-1A” (DYRK1A) to treat neuroinflammatory and neurodegenerative diseases such as Parkinson’s disease (PD).